To: Alys Hall who wrote (1159 ) 1/27/1998 2:54:00 AM From: Maurice Winn Respond to of 3702
"Or will we now be left with a debate, useless though it may be, on whether or not the stock gets delisted." I'm not sure, but I think with a market capitalisation of $28 million, Techniclone stays listed even though it might drop below $1. $1 is the limit for much lower capitalisations - not sure what, but I think more like a couple of million dollars. So there is a long way to go before you need contend with that. Maybe wrong, but that's my understanding. Even then, the assets of the company don't go away. You still own a going concern with maybe big profits to come. It is irrelevant to owners what new buyers are paying for shares - apart from dilution in which case you should be getting an opportunity before new shareholders to put more money in to maintain operations and your proportion of shareholding. I realize you need to have $1.10 to buy another share - but that is bad luck if you don't have it and the way dilution works. Although it looks very interesting to me, I haven't yet bought shares, because I'm not confident that the company has $34 million value. They bought back some rights to Oncolym as well as vasopermeation technology. Assuming they didn't pay too much, then that is a passable valuation of the company. Second hand furniture isn't too valuable. Suppose IDEC bought the assets, what do you suppose they'd pay? Surely not more than Lon Stone agreed to pay for the remaining Oncolym and vasopermeation rights. How about listing [for the ignorant potential new shareholders like me] the technology to which they hold exlusive rights and the valuations. Or direct me to the source of this information. If it looks good, we'll buy in and that will help hold the price and protect you against further dilution. I did see that Oncolym second year profits should = the market capitalisation [$30million]. Maybe. I'd have to work that out. At the moment it is an unproven bird in the bush having only completed preliminary trials for efficacy and safety on a few dozen people. Maurice